Anti-Human CD274/PD-L1 & CD137/TNFRSF9 Bispecific Reference Antibody (Acasunlimab, RUO)

Description: Acasunlimab (BS10671) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1;Lambda;Kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: B7-H1,Programmedcelldeath1ligand1,PDCD1ligand1,PDCD1L1,B7homolog1,PDCD1LG1,PDL1,hPD-L1,Programmeddeathligand1,B7H1,PD-L1,CD274,Tumornecrosisfactorreceptorsuperfamilymember9,CD137,4-1BBligandreceptor,CDw137,TNFRSF9,T-cellantigenILA,T-cellantigen4-1BBhomolog,ILA
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,BNT-311,DuoBody-PD-L1x4-1BB,GEN-1046,CAS:2253937-12-9
Background: Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.
Note: For research use only. Not suitable for clinical or therapeutic use.